© Borgis - Medycyna Rodzinna 2, p. 26-29
*Tomasz Wocial
Inhibitory pompy protonowej w chorobie refluksowej przełyku
Proton pump inhibitors in the management of gastroesophageal reflux disease
Klinika Gastroenterologii i Hepatologii CMKP, Centrum Onkologii, Warszawa
Kierownik Kliniki: prof. dr n. med. Eugeniusz Butruk
Summary
Gastroesophageal reflux disease (GERD) is a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. Symptoms occurring more than one day a week are considered troublesome by patients. Reflux esophagitis is the most common manifestation of esophageal injury. Chronic cough, laryngitis, asthma and dental erosions are recognised as possible extraesophageal manifestations of the disease. A diagnosis of GERD is confirmed if symptoms resolve during empirical proton pump inhibitor (PPI) therapy. In patients with atypical GERD syndromes high doses of PPI are recommended (the "omeprazole test”). Most patients need long-term treatment and PPI should be continued at the lowest dose that controls symptoms. A way of the maintenance treatment (continuous, intermittent or on-demand therapy) depends on the character of GERD symptoms or complications. Prolonged gastric acid suppression with PPI is safe, rarely produces serious adverse events and the withdrawal rate is very low.
Key words: gastroesophageal reflux disease, proton pump inhibitors, omeprazole test
Pi¶miennictwo
1. Vakil N., van Zanten S.V., Kahrilas T., i wsp. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol., 2006; 101: 1900-1920. 2.De Vault K.R., Castell D.O.: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterol., 2005; 100: 190-200. 3.Venables T.L., Newland R.D., Patel A.C., i wsp.: Omeprazole 10 mg, omeprazole 20 mg once daily or ranitidine 150 mg twice daily evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand. J. Gastroenterol., 1997; 32: 965-73. 4.Moss S.F., Armstrong D., Arnold R., i wsp.: GERD 2003 - a consensus on the way. Digestion 2003; 67: 111-117. 5.Richter E.J.: Extraesophageal presentations of gastroesophageal reflux disease: an overview. Am. J. Gasroenterol., 2000; 95 (Suppl.): S1-S3. 6.Moncur P.H., Heatley R.V.: Safety of proton-pump inhibitors: the acid test. Eur. J. Gastroenterol. Hepatol., 2000; 12: 145-147. 7.Numans M.E., Lau, de Wit N.J., i wsp.: Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann. Intern. Med., 2004; 140: 518-527. 8.Fass R., Ofman J.J., Sampliner R.E., i wsp.: The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosis gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment. Pharmacol. Ther., 2000; 14: 389-96. 9.Donnellan C., Sharma N., Preston C., i wsp.: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst. Rev., 2004; 4: CD003245. 10.Moayyedi P., Talley N.J.: Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-100. 11.Zacny J., Zamakhshary M., Sketris I., i wsp.: Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonist or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment. Pharmacol. Ther., 2005; 21: 1299-312. 12.Pace F., Negrini C., Wiklund I., i wsp.: Italian ONE investigators study group. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22: 349-56. 13.Dent J., Brun J., Fendrick A.M., i wsp.: An evidence-based appraisal of reflux disease management. The Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1-S16. 14.Richter J.: Ear, nose and throat and respiratory manifestations of gastro-esophageal reflux disease: an increasing conundrum. Eur. J. Gastroenterol. Hepatol., 2004; 16: 837-845. 15.Stedman C.A.M., Barclay M.L.: Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment. Pharmacol. Ther., 2000; 14: 963-978. 16.Laine L., Ahnen D., McClain C., i wsp.: Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment. Pharmacol. Ther., 2000; 14: 651-668. 17.Yeomans N.D., Dent J.: Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion? Aliment. Pharmacol. Ther., 2000; 14: 267-271. 18.Klinkenberg-Knol E.C., Nelis F., Dent J., i wsp.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9. 19.Kuipers E., Meuwissen S.G.: The efficacy and safety of long-term omeprazole treatment for gastroesopgageal reflux disease. Gastroenterology 2000; 118: 795-801. 20.Kujpers E.J., Nelis G.F., Klinkenberg-Knol E.C., i wsp.: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut., 2004; 53: 12-20. 21.Koury S.I., Stone C.K., La Charite D.D.: Omeprazole and the development of acute hepatitis. Eur. J. Emerg. Med., 1998; 5: 467-9. 22.Geevasinga N., Coleman P.L., Webster A.C.: Proton pump inhibitors and acute interstitial nephritis. Clin. Gastroenterol. Hepatol., 2006; 4: 597-604.
otrzymano/received: 2007-06-05
zaakceptowano/accepted: 2007-06-15
Adres/address:
*Tomasz Wocial
Klinika Gastroenterologii i Hepatologii CMKP
Centrum Onkologii – Instytut im. M. Skłodowskiej-Curie
ul. Roentgena 5, 02-781 Warszawa
tel. (0-22) 546-23-28, fax (0-22) 546-30-35
e-mail: wocialt@gazeta.pl
